Shares of Novavax, Inc. (NASDAQ:NVAX) fell -1.15% to reach at $5.14 during previous trading session. The company has experienced volume of 151,118 shares while on average the company has a capacity of trading 907.86K share.
Shares of Novavax, Inc. NVAX declined about 12% after the FDA recommended the company to conduct an additional phase III study for its respiratory syncytial virus (RSV) vaccine candidate for infants, ResVax.
ResVaxis being developed to protect infants by immunizing mothers against the disease, the leading viral cause of severe lower respiratory tract disease in infants and young children.
The FDA has recommended the additional to confirm efficacy against medically noteworthyRSV disease in infants born to mothers vaccinated with ResVax. In February 2019, the company declared that the phase III PREPARE study on ResVax did not meet the primary endpoint of prevention from medically noteworthyRSV and lower respiratory tract infection (LTRI).
However, the study did show efficacy against a secondary objective of preventing hospitalization, and is the first RSV vaccine to show phase III efficacy. This news led to the crashing of shares by more than 65% back then.However, Shares of Novavax have reduced 85.6% year to date against the industry’s increase of 1.9%.
Novavax has met with several European national regulatory agencies to get some inputs on the PREPARE study and also to find possible pathways to get marketing approval in Europe.
The development of ResVax was funded by a grants from Bill & Melinda Gates Foundation, to introduce ResVax to low and middle income countries.
Novavax has another vaccine candidate in its pipeline, influenza vaccine Nanoflu and is planning to initiate a phase III study on Nanoflu, following the successful completion of a phase II study earlier in January.
Some better-ranked stocks in the biotech sector are Anika Therapeutics Inc. ANIK, Applied Genetics Technologies Corp. AGTC and Acorda Therapeutics Inc. AXGT . All of them carry a Zacks Rank #1 (Strong Buy). You can see the complete list of recently’s Zacks #1 Rank stocks here.
Anika’s earnings per share estimates have moved up from $1.22 to $1.28 for 2019 and from $1.21 to $1.33 for 2020 in the past 60 days. The company delivered a positive earnings surprise in the trailing four quarters, with average beat of 72.00%.
Applied Genetics’ loss per share estimates have narrowed from $1.25 to 1 cent for 2019 and from $2.39 to $2.15 for 2020 in the past 60 days. The company delivered a positive earnings surprise in three of the trailing four quarters, with average beat of 83.47%.
Acorda’s loss per share estimates have narrowed from $3.84 to $3.59 for 2019 and from $3.32 to $3.09 for 2020 in the past 60 days. The company delivered a positive earnings surprise in all of the trailing four quarters, with average beat of 79.32%.
Novavax, Inc. (NASDAQ:NVAX) holds the market capitalization of $118.09M along with 22.71M outstanding shares. During the last trade, stock’s minimum price has been reached out at $0.34 while the maximum trading price moved at $51.60. Currently the stock price is moving 10.78% off from the highest level of twelve months and -90.04% above from twelve months low. Novavax, Inc. (NASDAQ:NVAX) marked 52-week highest price level of $51.60 on Aug 7, 2017 and 52-week lowest price level of $0.34 on Aug 11, 2017.
As of current trade, Novavax, Inc. (NASDAQ:NVAX) has shown weekly downbeat performance of -12.16%. Its six months performance indicated a bearish -88.34% movement while its yearly performance reflected a negative trend of -84.52%. Year-to-date (YTD) performance of the stock illustrate downbeat trend of -85.87%. Shares of Novavax, Inc. (NASDAQ:NVAX) currently have an ABR of 2.14, derived from a total of 7 opinions. The company’s price sits -37.69% below from its 50-day moving average of $7.05 and -81.48% below from the stock’s 200-day moving average of $24.58. The company has Relative Strength Index (RSI 14) of 32.19 along with Average True Range (ATR 14) of 0.57. Its weekly and monthly volatility is 8.25%, 7.04% respectively. The company’s beta value is at 2.32.
Novavax, Inc. currently has a PEG ratio of 0 where as its P/E ratio is 0. The company’s price to sales ratio for trailing twelve months is 4.13 and price to book ratio for most recent quarter is 0, whereas price to cash per share for the most recent quarter is 1.18. Novavax, Inc. (NASDAQ:NVAX)’s price to free cash flow for trailing twelve months is 0. Its quick ratio for most recent quarter is 3.90 along with current ratio for most recent quarter of 3.90. Total debt to equity ratio of the company for most recent quarter is 0 whereas long term debt to equity ratio for most recent quarter is 0. Novavax, Inc. (NASDAQ:NVAX) has a Return on Assets of -75.20%. The company currently has a Return on Equity of 136.30% and Return on Investment of 0.